Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy
journal contributionposted on 11.07.2019, 14:44 by Qian Chen, Guojun Chen, Jiawen Chen, Jingjing Shen, Xudong Zhang, Jinqiang Wang, Amanda Chan, Zhen Gu
Despite the promising efficacy of immune checkpoint blockade (ICB) in treating many types of cancers, the clinical benefits have often been restricted by the low objective response rates and systemic immune-related adverse events. Here, a bioresponsive ICB treatment is developed based on the reactive oxygen species (ROS)-sensitive protein complex for controlled sequential release of anti- “don’t eat me” signal antibody (aCD47) and antiprogrammed cell death protein 1 (aPD1), by leveraging the abundant ROS in the tumor microenvironment (TME). These protein complexes can also act as scavengers of ROS in the TME to reverse the immunosuppressive responses, thereby enhancing antitumor efficacy in vivo. In a melanoma cancer model, the synergistic antitumor efficacy was achieved, which was accompanied by enhanced T cell immune responses together with reduced immunosuppressive responses.